CMS seeks sickle cell gene therapy makers to participate in Medicaid drug model

The Centers for Medicare & Medicaid Services March 7 invited drug makers in the Medicaid Drug Rebate Program that make federally approved gene therapies for sickle cell disease to apply through May 1 to participate in the Cell and Gene Therapy Access Model. Announced in January, the model will negotiate rebate agreements with participating drug makers in an effort to increase access to treatments for Medicaid patients with rare and severe diseases, beginning with sickle cell disease. CMS expects states to apply this summer to participate in the voluntary model, which may also include the Children’s Health Insurance Program, depending on state and manufacturer interest.
Related News Articles
Headline
A JAMA study published yesterday analyzed the health characteristics of individuals projected to lose Medicaid coverage due to work requirements included in…
Headline
The Centers for Medicare & Medicaid Services Sept. 30 released guidance to states clarifying its interpretation of a provision that…
Headline
A bipartisan House letter by Reps. Dan Crenshaw, R-Texas, Yvette D. Clarke, D-N.Y., Gus M. Bilirakis, R-Fla., and Diana DeGette, D-Colo., urged House…
Headline
The AHA detailed its key health care priorities for the remainder of the year in comments to House and Senate majority and minority leaders Sept. 15. The AHA…
Headline
The Centers for Medicare & Medicaid Services Sept. 9 issued preliminary guidance regarding the implementation of certain state-directed payment provisions…
Headline
The AHA and other national hospital organizations Sept. 5 urged Senate and House leadership to act on preventing Medicaid Disproportionate Share Hospital…